Cebranopadol: Molecular Structure

Molecular Structure#

Cebranopadol is a synthetic small molecule with a distinctive spiro[cyclohexane-pyrano[3,4-b]indol] scaffold. Unlike traditional opioid analgesics, which are typically derived from morphinan or phenylpiperidine chemical classes, cebranopadol represents a novel chemical architecture specifically designed for dual NOP/opioid receptor engagement.

Chemical Identity#

Structural Features#

The cebranopadol molecule contains several notable structural elements:

1. Indole ring system: A 6'-fluorinated indole provides the core aromatic framework and contributes to NOP receptor binding
2. Pyran ring: Fused to the indole, creating a pyrano[3,4-b]indol system that constrains the molecular geometry
3. Spiro junction: The cyclohexane ring is connected to the pyrano-indole system through a spiro carbon, creating a rigid three-dimensional architecture
4. Dimethylaminophenyl group: At the 4-position of the cyclohexane ring, this basic nitrogen-containing group is critical for opioid receptor engagement
5. Fluorine substituent: The 6'-fluorine on the indole ring influences receptor selectivity and pharmacokinetic properties

Discovery and Design#

Cebranopadol was discovered at Grunenthal GmbH (Aachen, Germany) through systematic optimization of a spiro-indole lead series. The discovery paper (Schunk et al., ACS Med Chem Lett, 2014; PMID 25147603) describes how structure-activity relationship studies led to the identification of cebranopadol's unique ability to simultaneously engage NOP and opioid receptors with high potency.

Receptor Binding Profile#

The balanced NOP/MOP agonism is the defining pharmacological property. Pure MOP agonists (morphine, oxycodone, fentanyl) lack NOP activity, while the endogenous NOP ligand nociceptin/orphanin FQ has no opioid receptor affinity. Cebranopadol bridges these two systems.

Pharmacokinetics#

Cebranopadol exhibits pharmacokinetic properties favorable for once-daily oral dosing:

• Absorption: Tmax 4-6 hours after oral administration of the immediate-release formulation
• Distribution: Extensive tissue distribution
• Metabolism: Hepatic metabolism
• Half-life: Terminal half-life 62-96 hours; operational half-life ~24 hours
• Steady state: Reached in approximately 2 weeks with once-daily dosing
• Accumulation factor: ~2 at steady state
• Peak-trough fluctuation: 70-80% (relatively low, indicating stable plasma levels)

The long terminal half-life and low peak-trough fluctuation provide sustained plasma concentrations, supporting the long duration of analgesic effect observed in clinical trials (up to 22 hours from a single dose).

Comparison with Related Compounds#

Stability#

As a small molecule, cebranopadol has favorable stability characteristics compared to peptide therapeutics:

• Stable at room temperature in solid form
• Not susceptible to proteolytic degradation (unlike peptide ligands)
• No requirement for cold chain storage or reconstitution
• Suitable for conventional tablet or capsule formulations

Related Reading#

• Cebranopadol overview and research guide
• Peptides similar to cebranopadol
• Cebranopadol research evidence